Ligand id: 8406

Name: codrituzumab

1. Liu X, Wang SK, Zhang K, Zhang H, Pan Q, Liu Z, Pan H, Xue L, Yen Y, Chu PG. (2015)
Expression of glypican 3 enriches hepatocellular carcinoma development-related genes and associates with carcinogenesis in cirrhotic livers.
Carcinogenesis, 36 (2): 232-42. [PMID:25542894]
2. Nakano K, Ishiguro T, Konishi H, Tanaka M, Sugimoto M, Sugo I, Igawa T, Tsunoda H, Kinoshita Y, Habu K et al.. (2010)
Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization.
Anticancer Drugs, 21 (10): 907-16. [PMID:20847643]
3. Nakano K, Sugo I, Sugimoto M, Ishiguro T, Tanaka M, Iijima S. (2011)
Anti-glypican 3 antibody having modified sugar chain.
Patent number: US7867734 B2. Assignee: Chugai Pharmaceutical Co Ltd.. Priority date: 26/10/2004. Publication date: 11/01/2011.
4. Wu Y, Liu H, Weng H, Zhang X, Li P, Fan CL, Li B, Dong PL, Li L, Dooley S et al.. (2015)
Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway.
Int. J. Oncol., 46 (3): 1275-85. [PMID:25572615]
5. Yao M, Pan LH, Yao DF. (2015)
Glypican-3 as a specific biomarker for hepatocellular carcinoma.
HBPD INT, 14 (2): 122-3. [PMID:25865682]